Global Viral Vaccines Market Size By Technology (Recombinant & conjugate vaccines, Inactivated vaccines), By Indication (Pneumococcal disease, Meningococcal disease), By Distribution Channel (Hospital pharmacy, Online pharmacy), By End-User (Pediatric, Adult), By Route Of Administration (Oral, Injec
Published on: 2024-08-06 | No of Pages : 320 | Industry : latest updates trending Report
Publisher : MIR | Format : PDF&Excel
Global Viral Vaccines Market Size By Technology (Recombinant & conjugate vaccines, Inactivated vaccines), By Indication (Pneumococcal disease, Meningococcal disease), By Distribution Channel (Hospital pharmacy, Online pharmacy), By End-User (Pediatric, Adult), By Route Of Administration (Oral, Injec
Viral Vaccines Market Size And Forecast
Viral Vaccines Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2022 to 2030.
The global impact of COVID19 has been unprecedented and overwhelming, with vaccines positively impacting the demand in all regions amid the pandemic. The most powerful and affordable way to protect billions of people around the world. Vaccine development has the potential to transform health by lifting the burden of life-threatening infectious diseases in the populations of affluent nations. The World Health Organization (WHO) states that government initiatives have helped prevent 2-3 million deaths per year. The massive investment that goes hand in hand with corporate integration increases the production and sales of products around the world.
Global Viral Vaccines Market Definition
Vaccines are biological preparations, usually made from living organisms, that increase immunity against a specific disease. Vaccines that prevent the disease from occurring are called prophylactic vaccines, and in some cases, those that treat disease are called therapeutic vaccines. The four main types of vaccines are inactivated vaccines, live attenuated vaccines, conjugate vaccines, and toxoid vaccines.
Viral vaccines contain killed or attenuated viruses or their products, which can cause the immune system to make antibodies against them. An effective vaccine has eliminated a number of diseases, such as polio and smallpox, with a high mortality rate. Vaccines play an important role in maintaining sustainable human health in various countries.
Global Viral Vaccines Market Overview
The demand for vaccines has increased in recent years due to the increasing incidence of both bacterial and viral infectious diseases. Vaccines are essentially given to people of different ages, boosting their immune systems for life and providing protection against various types of infectious diseases. Due to the COVID19 pandemic, most healthcare, pharmaceutical, and biotech organizations have focused on diagnostic kits, wearable safety devices, and treatment vaccines and drugs for the novel coronavirus. Most of the leading companies are focused on finding an innovative vaccine against the new coronavirus. In addition, medical professionals started focusing more on novel coronavirus.
Additionally, pharmaceutical companies are prioritizing research and development of diagnostics, treatments, health technologies, and vaccines related to COVID19, as well as analyzing the potential of existing treatments. All these factors are expected to continue to impact the global Viral Vaccines Market in the future. The rise in the occurrence of numerous infectious and non-infectious sicknesses and technological improvements are projected to force the worldwide Viral Vaccines Market place all through the forecast period. According to the World Health Organization (WHO), numerous vaccines are in pipeline and currently in clinical trials. The rise in the number of vaccines in the pipeline is predicted to propel the worldwide Viral Vaccines Market place.
An increase in funding in the direction of improvement of recent vaccines is predicted to force the worldwide Viral Vaccines Market place withinside the coming years. For instance, researchers at Scripps Research Florida have been a success in growing a non-conventional vaccine to defeat SIVmac239 viral pressure labeled the “loss of life star” which offers long-lasting safety to uninfected people from more than one type of HIV stimulating the call for the vaccine. In addition, an upward push in the occurrence of numerous infectious illnesses and a boom in recognition concerning early sickness prognosis and prevention force the call for shielding vaccines; thereby, boosting the marketplace boom. Several efforts are taken by organizations, together with the UNICEF has multiplied the vaccine adoption over the years.
The Pan American Health Organization (PAHO) rotational fund and UNICEF donation agency allow for the purchase of low-cost vaccines in various countries. Every year, PAHO and UNICEF achieve goals for approximately 40 regions and around 100 countries, respectively thus, it has had a positive effect on the adoption rate. However, the high cost incurred in the research and development of vaccines is a major restraint for this market. Additionally, less penetration of awareness programs related to vaccination and health education in the less developed region seems to stay a major challenge for the market. Emerging economies, especially in China, India, and Southeast Asia are expected to widen opportunities due to a surge in awareness and disposable income.
Global Viral Vaccines Market Segmentation Analysis
The Global Viral Vaccines Market is segmented on the basis of Technology, Indication, Distribution Channel, End-User, Route Of Administration, And Geography.
Viral Vaccines Market, By Technology
• Recombinant & conjugate vaccines• Inactivated vaccines• Live attenuated vaccines• Toxoid vaccines• Others
Based on Technology, The market is segmented into Recombinant & conjugate vaccines, Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, and Others. Recombinant & conjugate vaccines account for the largest share in this segment due to incremental support from governments and a surge in company investments in the development of such vaccines.
Viral Vaccines Market, By Indication
• Pneumococcal disease• Meningococcal disease• Herpes zoster• Influenza• Combination vaccines• Polio• COVID-19• HPV• Rotavirus• MMR• Varicella• Hepatitis• DTP• Others
Based on Indication, The market is segmented into Pneumococcal disease, Meningococcal disease, Herpes zoster, Influenza, Combination vaccines, Polio, COVID-19, HPV, Rotavirus, MMR, Varicella, Hepatitis, DTP, and Others. Bacterial disease holds the largest share due to the high sales of pneumococcal, meningitis, and DTP worldwide. This is a first-line vaccine for newborns and an encouraging dose for pediatric infections. Part of the viral load is predicted to have a very high CAGR due to the forthcoming introduction of vaccines and increased sales of HPV and flu products. Recently, Janssen Pharmaceutical Companies announced the provision of the 200,000 Ebola program to Rwandan citizens in East Africa, with the aim of preventing the Ebola outbreak.
Viral Vaccines Market, By Distribution Channel
• Hospital pharmacy• Online pharmacy• Research institutes• Others
Based on Distribution Channel, The market is segmented into Hospital pharmacy, Online pharmacy, Research institutes, and Others. Hospitals and retail pharmacies are expected to have a high share because vaccines are a short-term procedure that is usually performed in small facilities. Hospitals and pharmacies around the world are monitored by the government to ensure that demand is met and that retailers have sufficient stock of stock. International government agencies such as the Global Alliance for Vaccines and Immunization (GAVI), UNICEF, Pan American Health Organization, and others are focused on achieving a sustainable global supply of products. These organizations receive volume from millions of manufacturers and focus on supplying countries with limited access. These organizations are expanding their geographical reach to Africa, the Middle East, Asia Minor, Latin America, and Europe. This is expected to increase the market value of the government’s supplier distribution channel in the coming years.
Viral Vaccines Market, By End-User
• Pediatric• Adult
Based on End-User, The market is segmented into Pediatric and Adult. The pediatric segment is expected to have a better market share due to the growing global birth cohort resulting in more vaccination. In the last two years due to the introduction of adult Covid-19 vaccines, this segment grew at a high rate and during the forecasted period the growth is expected to be increasing.
Viral Vaccines Market, By Route of Administration
• Oral• Injectable
Based on Route of Administration, The market is segmented into Oral and Injectable.
Viral Vaccines Market, By Geography
• North America• Europe• Asia Pacific• Rest of the world
On the basis of Regional Analysis, The Global Viral Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. A steady and dominant increase of the marketplace in North America is anticipated to develop regularly and is anticipated to preserve the dominant marketplace percentage because of the wide variety of things that encompass vaccination awareness, the presence of robust manufacturers, and steady authorities’ coverage concerning welfare. It additionally specializes in imposing immunization throughout the North American countries through good enough financing policies.
The Asia Pacific is anticipated to witness faster growth throughout the region. Japan dominates the Asia Pacific marketplace with the best marketplace percentage due to the growing population in China and India. This element is the primary element growing call for injections. On the opposite hand, Europe is projected to witness a consistent increase withinside the marketplace. Germany and France are probable to make contributions to the enlargement of the European marketplace. Latin America and Middle East & Africa are anticipated to check-in barely better increase because of the growing call for immunization to cater to the prevalence of chronic sicknesses that require vaccination specially withinside the African international locations.
Key Players
The “Global Viral Vaccines Market” study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer, Sanofi, GSK, Merck & Co., AstraZeneca plc, Serum institute of India Private Limited, Moderna, Novartis, and among others.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.
Key Developments
• April 2022 –ReViral is acquired by Pfizer. Due to this activity, Pfizer is now having ownership of the RSV viral vaccine development.
• April 2022 – Cadilla pharma launches novel 3 dose vaccine for rabies, naming ‘ThRabis’. This is having Virus-like Particle technology and recombinant nano-particle-based G protein vaccine by property.
• October 2021 – Pfizer receives US FDA Emergency Use Authorization (EUA) for Pfizer-BioNTech COVID-19 vaccine for children 5 to 11 years of age.
• August 2021 – The Pfizer-BioNTech COVID-19 COMIRNATY vaccine has received full US FDA approval for people 16 years and older.
• July 2021 – GSK gets US FDA approval for Shingrix (Zoster Vaccine Recombinant, Adjuvanted) to prevent shingles (herpes zoster) in adults 18 years and older who are at high risk of shingles or who will be at risk due to lack of protection allergies or allergies caused by a known disease or treatment.
• June 2021 – Merck announces launch of VAXELIS (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Active Poliovirus, Haemophilus Conjugate, and Hepatitis B Vaccine) in the US, developed in partnership with Sanofi Pasteur.
Report Scope
REPORT ATTRIBUTES | DETAILS |
---|---|
STUDY PERIOD | 2018-2030 |
BASE YEAR | 2021 |
FORECAST PERIOD | 2022-2030 |
HISTORICAL PERIOD | 2018-2020 |
KEY COMPANIES PROFILED | Pfizer, Sanofi, GSK, Merck & Co., AstraZeneca plc, Serum institute of India Private Limited, Moderna, Novartis, and among others. |
SEGMENTS COVERED | By Technology, By Indication, By Distribution Channel, By End-User, By Route Of Administration, And By Geography. |
CUSTOMIZATION SCOPE | Free report customization (equivalent up to 4 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope |
Top Trending Reports
Research Methodology of Market Research
To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .
Reasons to Purchase this Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post sales analyst support
Customization of the Report
• In case of any please connect with our sales team, who will ensure that your requirements are met.